Evidence map›Paper›PMID 34761304›Full record

ArticleVirchows Archiv : an international journal of pathology2022

Morphologic features in a series of 352 Spitz melanocytic proliferations help predict their oncogenic drivers.

Thibault Kervarrec, Daniel Pissaloux, Franck Tirode, Mahtab Samimi, Julien Jacquemus, Christine Castillo, Arnaud de la Fouchardière

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 30 citations in OpenAlex.

  1. Gene fusions in melanocytic lesions: an updated comprehensive review.Journal of pathology and translational medicine · 2026
    Article
  2. Article
  3. Spitz tumours and mimickers.Virchows Archiv : an international journal of pathology · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. The Morpho-Molecular Landscape of Spitz Neoplasms.International journal of molecular sciences · 2022
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Thibault KervarrecDepartment of Biopathology, Center Léon Bérard, Lyon, France. thibaultkervarrec@yahoo.fr.ORCID http://orcid.org/0000-0002-2201-6914
Daniel PissalouxDepartment of Biopathology, Center Léon Bérard, Lyon, France.
Franck TirodeCancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, INSERM 1052, CNRS, 5286, Lyon, France.
Mahtab SamimiBiologie des infections à Polyomavirus team, INRA UMR 1282 ISP, Université de Tours, Tours, France.
Julien JacquemusDepartment of Biopathology, Center Léon Bérard, Lyon, France.
Christine CastilloDepartment of Biopathology, Center Léon Bérard, Lyon, France.
Arnaud de la FouchardièreDepartment of Biopathology, Center Léon Bérard, Lyon, France.
Université Claude Bernard Lyon 1 · FRCentre Léon Bérard · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spitz nevi are indolent melanocytic tumors arising preferentially during and after childhood. Over the last decades, recurrent oncogenic drivers, sparsely detected in melanoma, were identified in Spitz melanocytic proliferations. Therefore, the detection of such drivers appears as a relevant diagnostic tool to distinguish both entities. Interestingly, morphologic features might correlate with the oncogenic drivers. Thus, the goal of this study was to assess the performances of previously identified morphological criteria to predict the presence of specific drivers. In total, 352 Spitz melanocytic proliferations either with a genetically identified oncogenic driver or investigated for ALK, ROS1, and NTRK1 overexpression by immunohistochemistry were enrolled in the present study. The microscopic features of the cases were assessed blindly with regards to the molecular status and, performances of previously described morphological criteria to predict the molecular status were assessed applying the likelihood-ratio test (LHR). Overall, an oncogenic driver was identified in 76% of the cases (n = 268/352). No microscopic features allowed the reliable prediction of ROS1- and NTRK1-overexpressing cases. By contrast, a plexiform pattern can contribute to the recognition of ALK-overexpressing cases (LHR(+) = 6.14). Importantly, the pseudo-schwannoma variant was highly suggestive of NTRK3-rearranged cases (LHR(+) = 43). Moreover, atypical/malignant tumor (LHR(+) = 5.18), severe cellular atypia (LHR(+) = 5.07), and p16 loss (LHR(+) = 14) contribute to the recognition of MAP3K8-rearranged cases, while the presence of a sheet-like architecture (LHR(+) = 5.39) and a marked fibrosis of the stroma (LHR(+)=5.06) were predictive of BRAF-fused tumors. To conclude, our study confirms ALK-overexpressing, NTRK3-, MAP3K8-, and BRAF-rearranged cases harbored distinct morphologic features allowing their microscopic recognition.

Indexed as

Proto-Oncogene Proteins B-rafSkin NeoplasmsCarcinogenesisChildHumansProtein-Tyrosine KinasesProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins B-rafReceptor Protein-Tyrosine KinasesFusionMorphologyOncogenic driverSpitz melanocytic proliferationSpitz naevus

Identifiers

PMID34761304
OpenAlexW3211427613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.